Mov Disord Vol 35, Suppl 1 Archives - Page 137 of 149 - MDS Abstracts

MDS Virtual Congress 2020
Serious games home rehabilitation program to treat gait and balance disorders in patients with Parkinson’s disease: A randomised controlled trial
D. Nuic, S. de Weijer, E. Zeeboer, C. Olivier, S. Cherif, P. Foulon, B.R Bloem, N. De Vries, M.L Welter (Paris, France)
Objective: To test the efficacy of an exergame rehabilitation programme at home to treat dopa-resistant gait and balance disorders in Parkinson’s disease (PD) patients. Background:…
MDS Virtual Congress 2020
Directional versus Omnidirectional Deep Brain Stimulation: Results of a Multicenter Prospective Blinded Crossover Study
A. Schnitzler, P. Mir, M.A Brodsky, L. Verhagen, S. Groppa, R. Alvarez, A. Evans, M. Blazquez, S. Nagel, W. Libionka, J. Pilitsis, M. Pötter-Nerger, W. Tse, L. Almeida, N. Tomycz, J. Jimenez-Shahed, F. Carrillo, C.J Hartmann, S.J Groiss, F. Defresne, E. Karst, B. Cheeran, J. Vesper (Plano, TX, USA)
Objective: To compare the range of stimulation amplitudes that can relieve symptoms without side effects, between directional and omnidirectional DBS. Background: Published reports on directional…
MDS Virtual Congress 2020
Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…
MDS Virtual Congress 2020
Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
A. Antonini, W. Poewe, J. Ferreira, G. Ebersbach, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Padova, Italy)
Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…
MDS Virtual Congress 2020
Non-pharmacological Treatment for Parkinson’s Disease Patients with Depression: A Meta-analysis of Repetitive Transcranial Magnetic Stimulation and Cognitive-Behavioral Treatment
J.N Chen, P.K He, Y.H Zhang, YY. Gao, Y.H Qiu, Y. Li, Q.X Zhang, L.M Wang, J.H Zhao, K. Nie, L.J Wang (Guangzhou, China)
Objective: This meta-analysis aims to assess the effect of non-pharmacological treatments for depression in patients with PD. Background: Antidepressants are the mainstay of treatment for…
MDS Virtual Congress 2020
Novel walker attachment for gait dysfunction in Parkinson’s disease: Case report
C. Gill, P. Schmitt, J. Karl, L. Verhagen Metman (Chicago, IL, USA)
Objective: To describe a patient with advanced PD who noted improved balance and fewer falls while using a novel belt attachment for his assistive device.…
MDS Virtual Congress 2020
Ceftriaxone improves motor function in a rat hemi-parkinsonian model: Potential to delay bilateral progression of motor deficits in Parkinson’s disease
E. Kasanga, C. McElroy, M. Salvatore (Fort Worth, TX, USA)
Objective: This study sought to evaluate the impact of ceftriaxone, as a potential repurposed drug, in ameliorating motor decline in a unilateral rat 6-hydroxydopamine (6-OHDA)…
MDS Virtual Congress 2020
Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model
M. Modaresi (Isfahan, Islamic Republic of Iran)
Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…
MDS Virtual Congress 2020
Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study
A. Saini, R. Rajan, R. Anandapadmanabhan, V. Venogopalan, A. Gupta, B. Verma, N. Choudhary, R. Bhatia, M. Singh, A. Srivastava, P. Srivastava (New Delhi, India)
Objective: To determine the cumulative anticholinergic burden in Indian Parkinson’s disease (PD) patients and to correlate the same with cognitive impairment and gait disturbance. Background:…
MDS Virtual Congress 2020
Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease
T. Viljakainen, M. Saarma, M. Voutilainen (Helsinki, Finland)
Objective: Investigate the effects of a peripherally administered novel neurotrophic compound, CMx01a, in 6-hydroxydopamine rat model of Parkinson’s disease. Background: Neurotrophic factors are promising drug…